Research analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the basic materials company’s stock.
Arcadia Biosciences Stock Up 2.2 %
Shares of Arcadia Biosciences stock opened at $2.79 on Tuesday. Arcadia Biosciences has a 12-month low of $1.85 and a 12-month high of $10.31. The company has a market capitalization of $3.81 million, a price-to-earnings ratio of -0.65 and a beta of 0.78. The firm’s 50-day moving average price is $3.88 and its two-hundred day moving average price is $4.13.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC bought a new stake in Arcadia Biosciences, Inc. (NASDAQ:RKDA – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned approximately 0.90% of Arcadia Biosciences as of its most recent filing with the SEC. 17.73% of the stock is owned by institutional investors.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- Investing in the High PE Growth Stocks
- Options Activity Points to More Volatility for Palantir Stock
- Do ETFs Pay Dividends? What You Need to Know
- NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?
- Most Volatile Stocks, What Investors Need to Know
- MicroStrategy Sees Insider Buy-Sell Action in Q1
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
